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Circulating tumor cells (CTC) are promising biomarkers in metastatic castration resistant prostate cancer (mCRPC), and telo-
merase activity (TA) is a recognized cancer marker. Therefore, we hypothesized that CTC TA may be prognostic of overall sur-
vival (OS) in mCRPC. To test this, we used a novel Parylene-C slot microfilter to measure live CTC TA in S0421, a phase III
SWOG-led therapeutic trial. Blood samples underwent CTC capture and TA measurement by microfilter, as well as parallel enu-
meration by CellSearch (Janssen/J&J). Cox regression was used to assess baseline (pre-treatment) TA versus OS, and recursive
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partitioning was used to explore potential prognostic subgroups and to generate Kaplan-Meier (KM) OS curves. Samples were
obtained from 263 patients and generated 215 TA measures. In patients with baseline CTC count 5 (47% of patients), higher
CTC TA was associated with hazard ratio 1.14 (p50.001) for OS after adjusting for other clinical covariates including CTC
counts and serum PSA at study entry. Recursive partitioning identified new candidate risk groups with KM OS curve separation
based on CTC counts and TA. Notably, in men with an intermediate range baseline CTC count (6–54 CTCs/7.5 ml), low versus
high CTC TA was associated with median survival of 19 versus 12 months, respectively (p50.009). Baseline telomerase activ-
ity from CTCs live-captured on a new slot microfilter is the first CTC-derived candidate biomarker prognostic of OS in a large
patient subgroup in a prospective clinical trial. CTC telomerase activity thus merits further study and validation as a step
towards molecular CTC-based precision cancer management.
Metastatic prostate cancer (PC) is the second most common
cause of cancer death in U.S. men.1 Although androgen
deprivation therapy is initially effective in this disease state,
response duration is highly variable. Eventually, most men
progress to metastatic castration resistant disease (mCRPC),
which is associated with overall survival of approximately 16
to 25 months.2,3 Individualized therapy of mCRPC has been
slow to develop due to a paucity of molecular biomarkers
associated with distinct prognostic subgroups as well as scant
available tumor tissue in advanced disease. Recently, these
unmet prognostic and predictive needs have been thrust into
high relief by a succession of new drugs that have emerged
for mCRPC, further emphasizing the need for improved
patient selection. As a result, novel PC biomarkers have been
urgently sought for disease detection, prognostication, predic-
tion of response to therapy, and for patient monitoring while
on therapy (reviewed in Ref. 4).
In recent years, analysis of circulating tumor cells (CTCs)
has garnered increasing attention as a potentially ready
source of cancer tissue with prognostic and predictive value
in metastatic prostate cancer.5–7 CTCs are cancer cells shed
by solid tumors into the peripheral blood, and CTC capture
and analysis allows repeated, minimally-invasive disease sam-
pling, thus offering the possibility of improved patient selec-
tion and real-time assessment of response to therapy.
Enumeration of CTCs has been prognostic in several large
prostate cancer trials,8–10 most recently in a phase III study
that we conducted in men with mCRPC treated with ﬁrst-
line chemotherapy.11 Additional efforts have been directed at
molecular characterization of CTCs for cancer-speciﬁc phe-
notypes such as the TMPRSS2-ERG fusion product or andro-
gen receptor mutations in mPC.6,12,13 Our own group also
has explored this approach, speciﬁcally focusing on CTC telo-
merase activity. Telomerase is an enzyme which lengthens
and protects telomeres, the tandem repetitive DNA sequences
that cap the ends of human chromosomes.14 Whereas benign,
terminally differentiated tissues have extremely low telomer-
ase levels, malignant cells from a variety of cancers have sig-
niﬁcantly elevated telomerase expression and telomerase
activity.15 The robust presence of telomerase in cancer cells
and its relative absence from benign tissues has led to a pro-
fusion of studies to assess its value as a biomarker, and telo-
merase activity has been shown to yield signiﬁcant diagnostic
and prognostic utility in prostate cancer16 and in a broad
spectrum of other malignancies.17–19
Reasoning that a telomerase-based biomarker strategy
would be applicable to nearly all solid malignancies, we set out
to analyze telomerase activity from live CTCs. This could not
be accomplished with the commercially available CellSearch
CTC enrichment platform (J&J), nor with our own prior
microﬁltration capture strategies,20,21 because all of these
required sample ﬁxation and did not yield live cells. Therefore,
we developed a new Parylene-C slot microﬁlter coupled to a
low constant pressure delivery apparatus designed to capture
live CTCs for telomerase activity measurement.22 To evaluate
the prognostic utility of CTC telomerase analysis in a prospec-
tive clinical cohort, we used the new slot microﬁlter platform
to capture live CTCs for telomerase activity measurement in
S0421, a SWOG Phase III Clinical Trial in mCRPC.11,23,24
Material and Methods
Study population
The “parent” trial for this CTC correlatives study was SWOG
Trial S0421 (Participants: SWOG, ECOG, CALGB), a North
American Intergroup Phase III trial for patients with mCRPC
involving bone who were randomized in a “double blind” man-
ner to docetaxel given every three weeks at a dose of 75 mg/m2
intravenously with oral daily prednisone in combination with
placebo or atrasentan, a novel endothelin 1 receptor antagonist
that inhibits osteoblast activity.23 S0421 had dual primary end-
points of overall survival (OS) and progression-free survival
(PFS), where progression was deﬁned as the conﬁrmed devel-
opment of new bone lesions, soft tissue or visceral progression
by RECIST criteria or symptomatic pain progression. Overall
What’s new?
Circulating tumor cells (CTC) are emerging as prognostic markers in castration-resistant prostate cancer. Here the authors
measured telomerase activity of live-captured CTCs in a Phase III prostate cancer trial. They found that telomerase activity
independently predicted overall survival in men with CTC counts 5 (hazard ratio 1.14; p50.001). Although these results
require confirmation, they underscore the clinical value of the molecular characterization of CTCs in the quest for
personalized cancer care.
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and progression-free survival were not signiﬁcantly different
between the placebo and atrasentan arms of SWOG S0421.23
Secondary endpoints related to evaluation of pain, patient
reported outcomes (quality of life), serum PSA kinetics
(including PSA response and progression as predictive and
prognostic factors), serum bone markers, and other transla-
tional endpoints.
CTC analysis in S0421 was proposed and funded after the
parent trial had been initiated. Speciﬁcally, CTC collection
was initiated in 7/2009, at which point approximately 630 of
planned 930 patients had already been accrued to S0421.
CTC collection ended with the closing of the parent trial in
7/2010, at which point 1,038 total patients had been regis-
tered to S0421. Therefore, there were approximately 400 eligi-
ble patients registered to S0421 during the period of active
CTC collection (7/2009–7/2010). Of these 400 eligible
patients, 263 (66%) submitted specimens for CTC telomerase
activity measurement. Of these 263 patients 215 (82%) had
telomerase activity (TA) assay results included in the
analysis.
Specimen collection
Blood samples for CTC analysis were collected in accordance
with a protocol amendment to S0421 that was reviewed and
approved by CTEP Central IRB as well as by each treating
institution’s IRB, and each patient gave informed consent.
Institutions registered to participate in S0421 were sent speci-
men collection kits containing blood collection tubes as well
as packing materials and return mailing labels. For each
patient, 7.5 ml of blood was drawn into an EDTA tube prior
to cycle 1 and 2 of chemotherapy (days 0 and 21) and
shipped overnight at room temperature to the University of
Southern California (USC) for CTC capture and telomerase
activity measurement. Each patient had an additional 7.5 ml
of blood drawn in parallel into a CellSave tube (Immunicon)
and shipped overnight at room temperature for CellSearch
CTC enumeration.
Sample processing
Upon arrival at USC, the peripheral blood sample was with-
drawn from the EDTA tube and subjected to Ficol-Paque
centrifugation to isolate the “buffy coat” containing periph-
eral blood mononuclear cells (PBMCs); these were collected
and the rest of the sample discarded. The PBMCs were
passed through two microﬁlter devices in series (Fig. 1) using
a low pressure delivery system as described previously (ﬁlter
1 captures CTC1 background white blood cells; ﬁlter 2 cap-
tures only background white blood cells).22 After ﬁltration,
the microﬁlters containing the trapped live cells were washed
13 with PBS. To lyse the cells, 50 ml of TRAPezeVR 1X
CHAPS Lysis Buffer (Millipore) was added directly to the ﬁl-
ters for 30 min on ice. The resulting cell lysates were col-
lected into a 1.7 ml eppendorf tube and centrifuged at 4C
for 20 min to remove cell debris. Telomerase activity was
measured using standard Telomeric Repeat Ampliﬁcation
Protocol (TRAP).25,26 Standard control samples were gener-
ated from serially-diluted lysates of DU145 prostate cancer
cell line and were run with every qPCR-TRAP reaction to
generate a standard curve which served both as a control for
the efﬁciency of the real-time PCR reaction and for normal-
ization and comparison of the unknown samples.
Data analysis and statistical considerations
Analyses were performed on the patients participating in the
CTC analysis with usable CTC lysate. Clinical characteristics
were tested between patients with high CTC TA (expressed
as Ct) versus low CTC TA, at randomization, using a cut-
point at the median TA measured from ﬁlter 1. Continuous
clinical covariates were tested by two-sided t-tests of unequal
variances; categorical covariates were tested by v2 tests.
We evaluated the association between CTC TA and OS
using Cox regression. We ﬁt models for baseline TA and a
number of derived variables (e.g., Ct ﬁlter 2 – Ct ﬁlter 1 for
ﬁlters run sequentially on the same specimen). Among the
models, we considered analyses adjusting for CTC counts,
and we considered analyses in subgroups deﬁned by CTC
counts (e.g., d0 CTC counts 5). Statistical signiﬁcance was
based on two-sided tests, and in this hypothesis generating
Figure 1. Scheme of CTC telomerase activity (TA) measurement by
slot microfilter. Each specimen was passed through two filters in
series. Filter-captured cells were lysed on filter, and the lysates
were analyzed for telomerase activity by qPCR-TRAP. CTC TA
equaled the difference between filter 1 and filter 2 (correction for
background telomerase activity signal from WBCs).
E
ar
ly
D
et
ec
ti
on
an
d
D
ia
gn
os
is
1858 CTC telomerase activity and prognosis in prostate cancer
Int. J. Cancer: 136, 1856–1862 (2015) VC 2014 UICC
analysis we considered statistical signiﬁcance to be p < 0.01.
All covariates were measured at baseline (d0).
All models were adjusted for a priori prognostic covari-
ates: treatment arm, (log 2) baseline CTC counts, (log2) base-
line PSA, age, race (African American vs. all other),
performance status, PSA-only progression versus radiologic
progression at study entry, worst bone pain 4, and extra-
skeletal mets: yes versus no. Factors with a p value >0.50
were not included in the multivariate models. In a further
exploratory analysis, prognostic subgroups were identiﬁed by
recursive partitioning analysis to ﬁnd the optimal cutpoint(s)
when considering the variables baseline CTC counts, TA, and
PSA.27 Kaplan-Meier survival curves were constructed for
each prognostic group. All analyses were done in R 2.15.1
(http://www.r-project.org/). Recursive partitioning was imple-
mented using R package ‘rpart’.
Results
The baseline demographic characteristics of patients participat-
ing in CTC correlatives were similar to those of the overall
population of S0421 with respect to age, race, bisphosphonate
use, pain assessment, extraskeletal metastases, Gleason score,
and baseline PSA (Supporting Information Table 1); there was
a suggestion that patients submitting specimens had better per-
formance status compared to those that did not participate
(p5 0.05) and may have had more measureable disease
(p5 0.08). In Table 1, patients with high TA tended to have
more extensive disease (p5 0.04) and a higher percentage with
race designated as black (p5 0.05). High versus low TA was
not signiﬁcantly associated with baseline PSA only versus clini-
cal progression, with bone pain, with bisphosphonate use, or
with treatment response (by PSA or RECIST). The TA values
(expressed as Ct) for the two in-series ﬁlters used to process
each sample had similar distributions. Both ﬁlters had a
median Ct 33 with an interquartile range of 31 to 34. Calcula-
tion of rank based correlation between the ﬁlters yielded a cor-
relation coefﬁcient of 0.53.
Absolute TA measured on either of the two ﬁlters was not
statistically signiﬁcantly associated with OS over the entire
cohort after adjusting for covariates, nor was the difference
in TA (Filter 2 – Filter 1) between ﬁlters and OS over the
entire cohort (Supporting Information Table 2). Exclusion of
likely technical outliers (Ct <20) or analysis only of high
telomerase activity specimens (Ct <32) or TA from d0 to
Table 1. Patient and disease characteristics for patients with valid
baseline filter 1 telomerase activity split at the median
Filter 1
Ct <33
(higher TA)
Filter 1
Ct 33
(lower TA) p
Total patients 103 112
Race: N (%)
Black 20 (0.19) 10 (0.09) 0.05
White 78 (0.76) 99 (0.88)
Other 5 (0.05) 3 (0.03)
Type of progression: N (%) 0.93
Measureable/Eval 86 (0.83) 94 (0.84)
PSA Only 17 (0.17) 18 (0.16)
Bisphosphonate usage: N (%)
No 37 (0.36) 36 (0.32) 0.56
Yes 66 (0.64) 76 (0.68)
Worst pain: N (%)
<4 57 (0.55) 63 (0.56) 0.89
4 46 (0.45) 49 (0.44)
Extraskeletal metastases: N (%)
No 39 (0.38) 58 (0.52) 0.04
Yes 64 (0.62) 54 (0.48)
Performance status: N (%)
0 50 (0.49) 54 (0.48) 1.00
1 45 (0.44) 49 (0.44)
2 7 (0.07) 8 (0.07)
3 1 (0.01) 1 (0.01)
Gleason’s: N (%)
<7 11 (0.11) 12 (0.11) 0.73
7 27 (0.26) 34 (0.30)
>7 62 (0.60) 61 (0.54)
Missing 3 (0.03) 5 (0.04)
Age at registration
Mean (SD; N) 68 (9; 103) 70 (9; 112) 0.08
Median (IQ range) 68 (62–74) 70 (63–76)
Baseline PSA
Mean (SD; N) 216
(401; 103)
239
(710; 112)
0.77
Median (IQ range) 79 (23–223) 76 (22–175)
Table 2. Multivariate proportional hazards model evaluating the
association between CTC telomerase activity and overall survival
(OS) in patients with 5 CTC by CellSearch (n5104) at baseline
(d0)
Variable HR for OS 95% CI p
d0 TA filter 221 1.14 (1.06–1.23) 0.001
d0 log2(CTC counts) 1.13 (1.02–1.26) 0.023
d0 log2(PSA) 1.09 (0.98–1.22) 0.11
Age 0.98 (0.95–1.00) 0.052
Black vs. Other race 0.60 (0.26–1.38) 0.22
Performance Status (0 vs. 1) 0.73 (0.46–1.17) 0.19
PSA only progression 1.95 (1.11, 3.44) 0.02
Atrasentan (vs. placebo) 0.84 (0.52–1.37) 0.49
Pain status, bisphosphonate usage and extraskeletal disease at study
entry were evaluated and removed from the model since they were
non-significant risk factors (p>0.50). Interaction of treatment arm
(atrasentan) with telomerase activity (TA filter 22 1) was not significant
(p > 0.05).
Abbreviation: HR5 hazard ratio.
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d21 also did not yield a statistically signiﬁcant association
between OS and Ct (data not shown).
Based on our prior published data,22 we reasoned that the
signal-to-noise capability of microﬁlter telomerase analysis
may not be sufﬁciently sensitive to detect the signal from very
few CTC superimposed on a background of residual WBCs.
Therefore, we examined the patient subgroup with 5 CTC
counted by CellSearch and estimated hazard ratios for an asso-
ciation between OS and TA. While no signiﬁcant association
was observed between CTC TA and OS on Filter 1 alone, the
difference in TA between ﬁlter 1 and 2—corresponding to the
TA attributable to CTC alone after correction for WBC back-
ground (Fig. 1 and Ref. 22)—was signiﬁcantly associated with
OS in men with 5 CTC counted by CellSearch. Speciﬁcally,
TAFilter 2 – TAFilter 1 had a statistically signiﬁcant OS HR of
1.14 (95% CI 1.06–1.23, p5 0.001) after adjusting for covari-
ates including baseline CTC counts (Table 2). The interaction
of TA with treatment arm was evaluated and found to be non-
signiﬁcant (p> 0.05), and so all analyses reported are for the
pooled treatment arms.
To further explore the prognostic roles of CTC counts and
telomerase activity in OS and also to evaluate the role of PSA,
we conducted a regression tree analysis for OS based on d0
CTC counts, d0 PSA, and d0 telomerase activity (TAﬁlter 2 –
TAﬁlter 1) using all patients with valid baseline data (n5 202).
This analysis showed that lower versus higher CTC telomerase
activity served as a prognostic cutpoint to further stratify
patients into distinct survival groups (Fig. 2): Speciﬁcally, in
Figure 2. KM overall survival curves by CART nodes baseline CTC counts and TA. Low versus high CTC TA connotes TA below or above the
median, respectively. p Value for comparison between nodes 2 and 3 (low vs. high TA)50.009 using 1 degree of freedom v2.
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men with intermediate range CTC counts between 6 and 54,
lower CTC TA was associated with a median OS of 19 months
whereas higher CTC TA was associated with a median OS of
only 12 months (p5 0.009). CTC TA at d0 was identiﬁed as a
signiﬁcant factor only in the subset of patients with d0
CTC counts of 6 to 54 but not in the low or high CTC count
groups.
Discussion
The high incidence and marked biological heterogeneity of
prostate cancer present a pressing need for improved prog-
nostic and predictive biomarkers, and CTC analysis may offer
valuable real-time insights that enhance personalized manage-
ment and facilitate disease monitoring. Telomerase is a tumor
marker with demonstrated diagnostic and prognostic utility in
multiple cancer types,15–19 and telomerase activity is not only
cancer-speciﬁc (relative to most benign tissues) and cancer-
universal (high in >90% of malignancies), but also constitutes
a uniquely “functional” assay that reﬂects the presence of live
cancer cells. Moreover, telomerase activity can be readily
ampliﬁed from as little as one cell using qPCR-TRAP to yield
quantitative data. Therefore, our goal in this study was to test
whether CTC telomerase activity measurement could serve as
a surrogate for CTC enumeration or perhaps even enhance
the prognostic utility of CTC counts. To address this question,
we collected and analyzed specimens from 263 patients in
S0421. While this cohort size was not as large as initially
expected (due to unexpected acceleration of accrual to the
parent trial prior to the inclusion of this biomarker substudy),
this nonetheless stands as the largest prospective cohort to
date with CTC biomarker correlatives in the ﬁrst-line doce-
taxel setting for mCRPC.
We assessed CTC TA parameterized in a variety of mod-
els in a hypothesis-generating approach, and most did not
yield a statistically signiﬁcant association with OS across the
entire participating cohort. However, we found that in the
subset of men with baseline (d0) CTC counts 5, higher
CTC telomerase activity was associated with worse overall
survival (OS) even after adjustment for other risks such as
baseline CTC counts, PSA level, and other clinical factors.
Furthermore, an exploratory regression tree analysis using
telomerase activity, CTC counts, and PSA level yielded prog-
nostic cutpoints based on CTC counts and telomerase activity
only, suggesting that in certain patient subgroups the prog-
nostic utility of CTC telomerase activity can potentially
exceed that of PSA. Such subgroups may be sizeable in this
advanced disease setting; for example, men with 5 CTC at
baseline—the group for which telomerase activity was prog-
nostic of OS—accounted for nearly half (47%) of patients for
whom telomerase measures were obtained in this study.
Telomerase activity was prognostic of OS only when
expressed as (TA Filter 2 – TA Filter 1), a necessary normaliza-
tion step proposed and tested previously to account for inter-
and intra-patient variations in WBC number and telomerase
activity over time and with therapy.22 Moreover, CTC telomer-
ase activity was signiﬁcantly associated with OS only when
measured in men with 5 CTC by CellSearch, a ﬁnding that
may reﬂect the inherent limits of detection of this assay. In
early experiments leading to the development of the slot
microﬁlter, the presence of residual background WBCs with
low telomerase activity on the ﬁlter generated a “signal to
noise” phenomenon: Speciﬁcally, whereas even single cancer
cells spiked into buffer with no background WBCs were detect-
able by qPCR-TRAP after capture on the microﬁlter, the telo-
merase activity of cancer cells spiked into 7.5 ml whole blood
was detectable down to 25 cancer cells due to residual back-
ground WBCs remaining on ﬁlter (103 range, similar to other
enrichment platforms).22 Thus, in S0421 CTC telomerase
activity was prognostic only in the 47% of patients with 5
CTC by CellSearch because perhaps only these patients had
sufﬁcient CTCs (relative to background WBCs) for detection
by this assay.
Another interesting consideration is the possibility that
telomerase activity may not simply function as a surrogate
marker for CTC numbers (i.e. the more CTCs, the more telo-
merase); rather, high telomerase levels within CTCs may itself
drive dissemination and aggressive disease. In the recursive
partitioning experiment (Fig. 2), low versus high telomerase
activity discriminated the KM survival curves for patients
with similar CTC counts (6–54 CTCs/7.5 ml), suggesting that
telomerase indeed may be discriminating a particular pheno-
type of aggressive CTCs rather than simply reﬂecting the
presence or absence of CTCs. Hence, telomerase activity may
represent more than a static surrogate for CTC counts, but
also a biologically relevant cancer property over time and
with exposure to therapy. The methods used in this study
may have not been as well suited to comparisons of TA over
time (e.g. d0 vs. d21) because of the residual WBCs remaining
on ﬁlter. Exposure to chemotherapy may impact WBC num-
bers and WBC TA differently than CTCs, resulting in
observed changes in CTC TA that may not be due to disease
response or progression alone but also due to changes in
background WBCs. Hence, the CTC TA methods used in this
study were best suited to determining CTC TA at one point
in time (e.g. baseline). Current work ongoing in our group
aims to address these limitations using new techniques to iso-
late ultra-pure CTC populations (no background WBCs) for
high precision TA comparison at multiple time points.
Telomerase activity assayed from live-captured CTCs was
prognostic of overall survival in a substantial subgroup of
patients in S0421, a large Phase III Intergroup trial of men
with mCRPC prospectively treated with ﬁrst-line docetaxel-
based chemotherapy. These results illustrate the prognostic
potential of CTC-derived biomarkers, and they are hypothesis
generating with regard to the use of telomerase as a CTC
biomarker in this disease setting. The near-ubiquity of telo-
merase elevation in cancer, coupled with the ever-widening
role of CTC collection in multiple malignancies, makes this a
promising biomarker strategy that merits additional investi-
gation and further validation in future studies.
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